Advances in chemotherapy of small cell lung cancer
10.3969/j.issn.1000-8179.2016.10.275
- VernacularTitle:小细胞肺癌药物治疗进展
- Author:
Mingyi DI
;
Li ZHANG
- Publication Type:Journal Article
- Keywords:
small cell lung cancer;
chemotherapy;
first-line therapy;
second-line therapy
- From:
Chinese Journal of Clinical Oncology
2016;43(10):418-423
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer (SCLC) accounts for about 13%of lung cancer. SCLC exhibits an early metastatic potential and sensitivi-ty to first-line cytotoxic chemotherapy compared with non-small cell lung cancer. Current treatments include surgery, radiotherapy, and chemotherapy. Platinum plus etoposide is viewed as the standard first-line chemotherapy. However, recurrence rate of cancer af-ter platinum plus etoposide chemotherapy is high. Topotecan monotherapy is the standard second-line chemotherapy. Meanwhile, novel targeted immunotherapy showed poor effects. Hence, new breakthroughs in the treatment of SCLC are urgently needed.
